R. E. Schwartz

The paper identifies Hippo kinases as inhibitors of PI3K alpha, showing epinephrine activates these kinases to suppress insulin signaling and glucose metabolism.

This study investigates SARS-CoV-2 infection in placentas from infected pregnant women, finding that the virus infects syncytiotrophoblast cells and triggers maternal immune cell infiltration.

This study shows coagulation factors like factor Xa and thrombin directly cleave SARS-CoV-2 spike, enhancing viral entry, and suggests anticoagulation could reduce infection.

This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.

This study identifies Alectinib as an FDA-approved drug that inhibits SARS-CoV-2 nucleocapsid phosphorylation and viral replication in vitro by targeting host kinases.

This study uses hPSC-derived lung organoids to identify FDA-approved drugs that inhibit SARS-CoV-2 entry and reduce infection in a model of human COVID-19.

This study uses human pluripotent stem cell-derived colonic organoids to identify drugs that block SARS-CoV-2 infection, finding mycophenolic acid and quinacrine dihydrochloride effective in vitro and in vivo.

This study examines HCQ's transcriptomic effects in vitro and finds limited overlap with SARS-CoV-2 host response genes, suggesting limited immunomodulatory evidence for HCQ in COVID-19.

This study evaluates the long-term biocompatibility and biodistribution of single-walled carbon nanotubes in mice after intravenous administration, finding low-level persistence and no adverse effects.